Biogen Beats Quarterly Estimates on Drug Sales
Biogen reported third quarter results that topped Wall Street estimates driven by robust demand for rare disease treatments and its Alzheimer drug Leqembi. The drugmaker also raised the lower end of its full year adjusted profit forecast.
Xurve View
Insights:
Xurve View
BIOGEN INC reported third-quarter revenue rose 11% to $2.80B on Wednesday afternoon, beating Wall Street estimates of $2.63B.
